Your browser doesn't support javascript.
loading
External Beam Radiotherapy for Medullary Thyroid Cancer Following Total or Near-Total Thyroidectomy.
Jin, Michael; Megwalu, Uchechukwu C; Noel, Julia E.
Affiliation
  • Jin M; Department of Otolaryngology-Head and Neck Surgery, School of Medicine, Stanford University Stanford, California, USA.
  • Megwalu UC; Department of Otolaryngology-Head and Neck Surgery, School of Medicine, Stanford University Stanford, California, USA.
  • Noel JE; Department of Otolaryngology-Head and Neck Surgery, School of Medicine, Stanford University Stanford, California, USA.
Otolaryngol Head Neck Surg ; 164(1): 97-103, 2021 01.
Article in En | MEDLINE | ID: mdl-32746731
OBJECTIVES: Medullary thyroid carcinoma (MTC) often presents with advanced disease and takes an aggressive course as compared with more well-differentiated thyroid cancers. The role of adjuvant therapy, specifically external beam radiotherapy (EBRT), remains disputed. This study investigated the impact of EBRT on survival in MTC. STUDY DESIGN: Cross-sectional analysis of a national database. SETTING: Patients with MTC were identified from the SEER program (Surveillance, Epidemiology, and End Results). METHODS: Collected variables included age, sex, race, T and N stages, lymph node yield, and use of EBRT. Propensity score matching was performed to determine the association of EBRT with overall and disease-specific survival. RESULTS: A total of 2046 patients with locoregional MTC were identified. Of these, 152 received EBRT. Patients receiving EBRT were older and had more advanced disease. EBRT was not associated with differences in overall survival (hazard ratio, 1.12; 95% CI, 0.76-1.65) or disease-specific survival (1.66; 0.93-2.95), as well as in subset analysis of age and disease extent. Long-term overall survival was similar, with 77.3% (95% CI, 70.1%-85.3%) and 58.3% (48.2%-70.5%) of patients without EBRT alive at 5 and 10 years, respectively (vs 70.7% [63.2%-79.1%] and 52.3% [43.3%-63.2%] of patients with EBRT). There were no differences in 5- and 10-year disease-specific survival. CONCLUSION: EBRT was not associated with improved overall or disease-specific survival in patients with MTC. Decisions regarding EBRT must be made with consideration of morbidity relative to benefit for individual patients.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Thyroid Neoplasms / Carcinoma, Neuroendocrine / Radiotherapy, Adjuvant Type of study: Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Limits: Female / Humans / Male / Middle aged Language: En Journal: Otolaryngol Head Neck Surg Journal subject: OTORRINOLARINGOLOGIA Year: 2021 Document type: Article Affiliation country: Country of publication:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Thyroid Neoplasms / Carcinoma, Neuroendocrine / Radiotherapy, Adjuvant Type of study: Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Limits: Female / Humans / Male / Middle aged Language: En Journal: Otolaryngol Head Neck Surg Journal subject: OTORRINOLARINGOLOGIA Year: 2021 Document type: Article Affiliation country: Country of publication: